Harvest One Cannabis Inc.(TSXV:HVST) is pleased to advise that the Patent Cooperation Treaty (“PCT”) application submitted by the Company’s Swiss-based subsidiary Satipharm AG (“Satipharm“) in February 2017 has now been published. This comprehensive patent application is directed at Satipharm’s proprietary Gelpell-CBD product technology, and covers oral formulations utilising both singular and/or a combination of cannabinoids. Once granted, the patent will be owned equally by Satipharm and its manufacturing partner Gelpell AG (“Gelpell”) and will also cover, via an exclusive agreement, the cannabis-derived prescription drugs developed by PhytoTech Therapeutics Limited (“PTL”).
The unique Gelpell-CBD product technology enables flexibility in manufacturing a wide range of doses at various ratios of cannabinoids that can be used for multiple indications and personalised medicine.
In 2016, Satipharm signed an exclusive license agreement with Gelpell (the “License Agreement“) to develop and sell products using Gelpell’s proprietary technology, for the treatment or prevention of any medical condition or disease in humans and animal and for food and dietary supplements. Under the terms of the licence, the parties agreed that all intellectual property generated under the licence will be jointly owned between Gelpell and Satipharm, but Satipharm will maintain exclusivity to any licenced intellectual property. Satipharm has, in turn granted PTL the exclusive rights to exploit the Gelpell IP in the worldwide pharmaceutical field (excluding Canada).
Andreas Gedeon, Harvest One’s CEO commented, “This patent progression is a key development for our research and development team, and reaffirms the Company’s commitment to strengthening its intellectual property portfolio. We remain focused on expanding our R&D capabilities and we look forward to providing further updates on this division in due course.”
Harvest One advises the Company will provide a comprehensive corporate update to the market in the coming weeks.
About Harvest One
Harvest One Cannabis Inc.(TSXV:HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation license, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the PCT application. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
For more information on Harvest One Cannabis, please contact: Colin Clancy Communications Manager +1 (778) 855-2408 firstname.lastname@example.org
Click here to connect with Harvest One Cannabis Inc. (TSXV:HVST) to receive an Investor Presentation.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).